New York State Common Retirement Fund Vor Biopharma Inc. Transaction History

New York State Common Retirement Fund

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 31, 2024	SELL	$1.0 - $2.2 $21,545 - $47,399	-21,545 Reduced 98.53%	322 $0
Q1 2024 May 07, 2024	BUY	$1.8 - $2.85 $669 - $1,060	372 Added 1.73%	21,867 $52,000
Q4 2023 Feb 01, 2024	SELL	$1.66 - $2.63 $200 - $318	-121 Reduced 0.56%	21,495 $48,000
Q3 2023 Nov 07, 2023	BUY	$2.1 - $3.35 $873 - $1,393	416 Added 1.96%	21,616 $46,000
Q2 2023 Aug 07, 2023	BUY	$3.09 - $5.33 $65,508 - $112,996	21,200 New	21,200 $66,000
Q2 2022 Aug 04, 2022	SELL	$3.89 - $6.44 $40,860 - $67,645	-10,504 Reduced 98.22%	190 $1,000
Q1 2022 May 05, 2022	BUY	$6.04 - $12.23 $271 - $550	45 Added 0.42%	10,694 $65,000
Q4 2021 Feb 02, 2022	BUY	$11.32 - $18.02 $32,182 - $51,230	2,843 Added 36.42%	10,649 $124,000
Q3 2021 Nov 02, 2021	SELL	$12.24 - $20.38 $42,668 - $71,044	-3,486 Reduced 30.87%	7,806 $122,000
Q2 2021 Aug 02, 2021	BUY	$18.65 - $38.78 $50,205 - $104,395	2,692 Added 31.3%	11,292 $211,000
Q1 2021 May 11, 2021	BUY	$30.96 - $54.08 $266,256 - $465,088	8,600 New	8,600 $371,000

41.2M

9.3K

100

Ticker VOR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,056,300
Market Cap $33.1M
Description
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AM...

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

Stay updated on New York State Common Retirement Fund with notifications on news.